Author(s)

He Xinbin, He Chong, Sun Guoxiang, Jiang Hongmei, Xiao Yongjun, and Hu Qilong

Corresponding Author

He Xinbin

Abstract

Both prostate cancer and bladder cancer are common tumors in the genitourinary system[1]. While the incidences of both the two cancers are increasing, it is rare that the primary tumors of them occur at the same time in clinical practice .When both of them coexist at the same time, the treatment method will be complicated, and they often lose control after conventional treatment. Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor, stem cell factor receptor and other kinases.

Keywords

Prostate cancer; bladder cancer; Anlotinib; double primary cancer